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ABSTRACT
Introduction The COVID-19 pandemic is ongoing, yet, 
due to the lack of a COVID-19- specific tool, clinicians 
must use pre- existing illness severity scores for initial 
prognostication. However, the validity of such scores in 
COVID-19 is unknown.
Methods The North West Collaborative Organisation for 
Respiratory Research performed a multicentre prospective 
evaluation of adult patients admitted to the hospital with 
confirmed COVID-19 during a 2- week period in April 
2020. Clinical variables measured as part of usual care 
at presentation to the hospital were recorded, including 
the Confusion, Urea, Respiratory Rate, Blood Pressure and 
Age Above or Below 65 Years (CURB-65), National Early 
Warning Score 2 (NEWS2) and Quick Sequential (Sepsis- 
Related) Organ Failure Assessment (qSOFA) scores. The 
primary outcome of interest was 30- day mortality.
Results Data were collected for 830 people with 
COVID-19 admitted across seven hospitals. By 30 days, 
a total of 300 (36.1%) had died and 142 (17.1%) had 
been in the intensive care unit. All scores underestimated 
mortality compared with pre- COVID-19 cohorts, and overall 
prognostic performance was generally poor. Among the 
‘low- risk’ categories (CURB-65 score<2, NEWS2<5 and 
qSOFA score<2), 30- day mortality was 16.7%, 32.9% and 
21.4%, respectively. NEWS2≥5 had a negative predictive 
value of 98% for early mortality. Multivariable logistic 
regression identified features of respiratory compromise 
rather than circulatory collapse as most relevant 
prognostic variables.
Conclusion In the setting of COVID-19, existing prognostic 
scores underestimated risk. The design of new prognostic 
tools should focus on features of respiratory compromise 
rather than circulatory collapse. We provide a baseline 
set of variables which are relevant to COVID-19 outcomes 
and may be used as a basis for developing a bespoke 
COVID-19 prognostication tool.
INTRODUCTION
The novel coronavirus SARS- CoV-2 is causing a 
global pandemic of the infectious disease termed 
COVID-19. COVID-19 is frequently associated 
with a pneumonia syndrome and the large 
ISARIC (International severe acute respiratory 
and emerging infection consortium) observa-
tional study estimates a case fatality rate of 33% 
among those admitted to hospital.1 Prognostic 
scores can improve clinical decision making, 
and pre- COVID-19 several scores had been 
extensively validated and supported by national 
and international guidelines for application in 
the context of acute infectious disease.2–4
The Confusion, Urea, Respiratory Rate, 
Blood Pressure and Age Above or Below 65 
Years (CURB-65) score is a community- acquired 
pneumonia (CAP)- specific tool for predicting 
all- cause mortality within 30 days. CURB-65 
has been validated across large, diverse patient 
populations and has been endorsed by national 
and international guidelines as an aid to clin-
ical decision making.5–9 The National Early 
Warning Score 2 (NEWS2) is a scoring system 
based on routine physiological measure-
ments, and its implementation into all English 
National Health Service (NHS) hospitals has 
beenbmandated in the pre- COVID-19 era.10 
NEWS2 is a disease agnostic early warning tool 
used to trigger escalation of care in the dete-
riorating patient, with high scores being asso-
ciated with death or unanticipated intensive 
care unit (ICU) admission within 24 hours.2 
The Quick Sequential (Sepsis- Related) Organ 
Failure Assessment (qSOFA) score is a tool for 
predicting mortality and ICU admission among 
patients with suspected infection in prehospital, 
emergency department and ward settings. It has 
been validated through large datasets, and has 
gained prominence following its recommenda-
tion by the Sepsis-3 task force.4 11
At the onset of the UK epidemic, in the 
absence of COVID-19- specific prognostic 
tools, CURB-65, NEWS2 and qSOFA remained 
in widespread use, but little was known about 
their validity in the COVID-19 setting. The 
primary aim of this study was to determine the 
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the context of COVID-19 and, secondarily, to investigate 
potential components of a COVID-19- specific prognosti-
cation tool for future validation.
METHODS
Study setting and participants
The North West Collaborative Organisation for Respiratory 
Research (NW- CORR) collected data during the 2- week 
period from 1 April 2020 to 14 April 2020 on prospective 
adult COVID-19 admissions at seven acute hospitals in 
North West England. NW- CORR constitutes a group of 
research- interested, respiratory, specialist trainee grade 
doctors, and the recruiting centres were those with an 
NW- CORR member available. Collaborators were asked 
to record routinely collected clinical data for consecutive 
patients admitted to their hospitals who met the Public 
Health England inpatient case definition for COVID-1912 
and had a positive SARS- CoV-2 PCR test. There were no 
exclusion criteria. No approach to the patient was made, 
and only fully anonymised, routinely available clinical infor-
mation was collated; on this basis, consent was not required 
under pandemic- specific guidance from the NHS Human 
Research Authority (https://www. hra. nhs. uk/ covid- 19- 
research/ guidance- using- patient- data/).13
Patient and public involvement
Healthcare professionals with COVID-19 were involved 
in the design, conception and conduct of the study. All 
agreed the project was desirable and non- intrusive for 
patients and deliverable during a time of crisis.
Outcomes and prognostic scores
Data collected included demographic characteristics, 
vital signs and blood test results. All physiological values 
and blood results constituting components of the CURB-
65, NEWS2 and qSOFA scores were the earliest measure-
ment recorded in the hospital. The variables included 
in each risk score are shown in table 1. At the point of 
data entry, collaborators were also asked to comment 
on the presence or absence of consolidation on chest 
radiography. Outcomes studied were 30- day all- cause 
mortality, 72- hour mortality and ICU admission. With 
respect to the three risk scores, these outcome measures 
are in some cases validated and in other cases unvalidated 
but widely applied in clinical practice; in the unvalidated 
context, the analysis was therefore exploratory.
Data handling
Anonymised study data were collated centrally and 
managed using the secure, web- based software platform 
Research Electronic Data Capture (Vanderbilt University, 
USA) hosted at the University of Liverpool. In general, 
there were minimal missing data with >99% complete-
ness for all constituent variables of the three prognostic 
scores (table 2 and figure 1).
Statistical analysis
Scores were assessed individually against their validated 
outcomes and overall for their ability to identify people at 
risk of mortality within 72 hours (early death) and 30 days 
of admission. This analysis included sensitivity and spec-
ificity of each score’s respective risk strata followed by an 
evaluation of discrimination and calibration in keeping 
with TRIPOD guidelines.14 Discriminatory ability was 
assessed by comparison of the corresponding receiver 
operating characteristic curves with computation of area 
under the curve (AUC). Calibration was assessed visually 
by plotting the observed risk for a score’s individual strata 
against published reference risk derived from their orig-
inal validation. In order to allow direct comparison of the 
clinical scoring systems, only patients with complete data 
for all variables were included in comparative statistical 
analyses. Data for the clinical parameter Clinical Frailty 
Scale (CFS) score was missing from one centre where 
this data was not recorded; since this was confined to one 
centre and therefore was not randomly missing, analyses 
were restricted the population where all variables were 
available.
Multiple logistic regression models were fitted for each of 
the outcome variables (30- day mortality, 72- hour mortality 
and ICU admission) using each score (CURB-65, NEWS2 
and qSOFA). With the aim of identifying variables relevant 
to COVID-19 outcomes and in order to assess the association 
of each individual variable (eg, age and respiratory rate) 
with each of the outcomes, multiple regression modelling 
using all variables was fitted by applying backward variable 
selection. Data heterogeneity introduced by differences 
among hospitals was assessed by adding a random inter-
cept in the model. However, clustering by hospital did not 
improve the accuracy of the model, and the final models did 
not include a random term. The performance of the fitted 
models was assessed by sensitivity, specificity, positive predic-
tive value (PPV), negative predictive value (NPV) and AUC. 
These analyses were performed using the statistical software 
package pROC in R V.3.5.3. pROC features internal cross 
validation based on bootstrap sampling method.




 ► Urea>7 mmol/L
 ► Respiratory rate: 
30 breaths/min
 ► BP: systolic<90 or 
diastolic 60 mm 
Hg
 ► Age 65 years
 ► Respiratory rate
 ► SpO2
 ► Supplemental 
O2 use
 ► Heart rate
 ► Altered 
consciousness
 ► Temperature
 ► Altered mental 
status
 ► Respiratory 
rate: 22 
breaths/min
 ► BP: systolic 
100 mm Hg
CURB-65, Confusion, Urea, Respiratory Rate, Blood Pressure and 
Age Above or Below 65 Years; NEWS2, National Early Warning 
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RESULTS
Data were collected and recorded for 830 patients 
admitted to seven hospitals in the North West of England, 
encompassing both secondary and tertiary care hospi-
tals (see online supplemental material). Clinical char-
acteristics and observations at admission are presented 
in table 2. Overall, 509/830 (61.3%) were male with a 
median age of 70 years (IQR 58–80) and a Rockwood 
CFS score of 4 (IQR 2–6). Within 72 hours of admission, 
63/830 (7.6%) patients had died and 125/830 (15.0%) 
had been admitted to ICU. At 30 days, 300/830 (36.1%) 
had died; 452/830 (54.5%) has been discharged; and 
78/830 (9.4%) remained in the hospital. During the 
30- day period, 142 (17.1%) were admitted to critical 
care, of whom 65 (45.8%) died. A comparison of clinical 
characteristics based on 30- day and 72- hour mortality is 
presented in table 2 and online supplemental table S1, 
respectively.
The discriminatory ability of each score was assessed for 
death within 30 days, death within 72 hours and admission 
to critical care, and are presented in figure 2. In general, 
performance was modest, with AUCs ranging from 0.62 
to 0.77. Calibration was computed by comparing the 
predicted risk from each score against the respective 
observed risk in the study cohort. Visual comparison of 
each calibration plot confirmed slopes of >1 and inter-
cepts of >0, suggestive of underestimation (see figure 3).
To test scores’ performance at their individual vali-
dated thresholds, the sensitivity, specificity, NPV and PPV 
were calculated for patients with complete datasets (see 
figure 1) and are presented in table 3. Overall, for 30- day 
mortality, scores failed to accurately identify a low- risk 
group, with mortality in the lowest- risk strata ranging 
from 16% to 33%. For 72- hour mortality, a CURB-65 
threshold of 2 and A NEWS2 threshold of 5 both identi-
fied a low- risk group with just 2-3% mortality and NEWS2 
achieved a sensitivity of 92% with an NPV of 98%. All 
scores performed poorly in predicting admission to 
ICU (see online supplemental table S2). The relative 
likelihood of mortality at each stratum of each score is 
presented in table 4.
When all individual variables were considered, multi-
variable logistic regression revealed that confusion and 
blood pressure (BP) were less relevant to 30- day mortality 
Table 2 Baseline demographics and clinical characteristics with comparison by outcome at 30 days
Missing All
Death by 30 days
Alive Dead P value
n 830 530 300
Characteristics at presentation
  Age (years) 1 (0.1) 70 (58–80) 65 (55–76) 76 (67–85) <0.001
  Sex (male) 0 (0.0) 509 (61.3) 309 (58.3) 200 (66.7) 0.02
  CFS score 81 (9.8) 4 (2–6) 3 (2–5) 5 (3–6) <0.001
  Temperature (°C) 3 (0.4) 37.5 (36.8–38.2) 37.4 (36.8–38.1) 37.6 (36.8–38.4) 0.15
  Respiratory rate (breaths/min) 2 (0.2) 24 (20–28) 22 (20–26) 24 (21–30) <0.001
  Heart rate (beats/min) 1 (0.1) 94 (82,108) 95 (82–108) 91 (80–110) 0.28
  Systolic BP (mm Hg) 2 (0.2) 130 (115–145) 130 (117–145) 131 (113–145) 0.78
  Diastolic BP (mm Hg) 2 (0.2) 75.0 (65.0–84.0) 76.0 (67.0–85.0) 72 (63–81) <0.001
  SpO2 1 (0.1) 94 (90–96) 94 (91–96) 93 (89–96) 0.002
  Supplemental oxygen (%) 2 (0.2) 340 (41.0) 183 (34.5) 157 (52.3) <0.001
  SpO2:FiO2 ratio 2 (0.2) 414 (283 to 448) 429 (339 to 452) 354 (189 to 443) <0.001
  Confusion 0 (0.0) 183 (22.0) 90 (17.0) 93 (31.0) <0.001
Investigations
  Urea (mmol/L) 8 (1.0) 7.2 (4.9–11.1) 6.3 (4.6–9.2) 9.8 (7.0–15.1) <0.001
  Consolidation 4 (0.5) 684 (82.8) 425 (80.5) 259 (86.9) 0.02
  CRP (mg/L) 10 (1.2) 104.0 (47.8–173.1) 92.0 (42.5–158.0) 117.0 (59.0–195.0) <0.001
  WCC (109/L) 4 (0.5) 7.4 (5.6–10.1) 7.3 (5.5–9.8) 7.6 (5.7–10.6) 0.20
  Neutrophils (109/L) 7 (0.8) 5.8 (3.9–8.55) 5.6 (3.8–7.9) 5.9 (4.0–9.1) 0.26
  Lymphocytes (109/L) 9 (1.1) 0.8 (0.6–1.1) 0.9 (0.6–1.2) 0.7 (0.5–1.0) <0.001
  NLR 9 (1.1) 154.0 (91.0–201.0) 155.0 (95.5–201.0) 152.5 (85.3–201.0) 0.62
P values are calculated using Fisher’s exact test for categorical variables, Mann- Whitney test for continuous variables since none of the 
continuous variables follow the assumption of normality (Shapiro normality test p value of ≤0.001 for all of them)
Data are presented as n (%) or median (IQR).
BP, blood pressure; CFS, Clinical Frailty Scale; CRP, C reactive protein; FiO2, fraction of inspired oxygen; NLR, neutrophil:lymphocyte 
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than urea, respiratory rate and age when computed as 
part of the CURB-65 score (see online supplemental 
table S3). In a similar fashion, the most severe BPs and 
HR strata in NEWS2 (score of 3: systolic BP≤90 mm Hg, 
HR>130 or <41/min) were not independently associated 
with poorer outcomes in the NEWS2 model (see online 
supplemental table S4), whereas the corresponding 
fraction of inspired oxygen (FiO2) and respiratory rate 
strata were relevant to mortality (OR 2.00 (1.4–2.8), 
p<0.001 and OR 1.9 (1.3–2.9), p=0.003, respectively).
Finally, a backward selection multivariable model fitted 
for each outcome identified de novo a set of variables 
independently associated with 30- day mortality (Clin-
ical Frailty Scale, Urea, Consolidation, Age, FiO2, Sex, 
Respiratory rate (CUCAF- SR)) and a similar set of vari-
ables for 72- hour mortality (Clinical Frailty Scale, Urea, 
Figure 1 Patient flowchart describing cohort for each analysis and missing data. Analysis of CURB-65 scores was restricted 
to patients with consolidation on chest radiograph. CURB-65, Confusion, Urea, Respiratory Rate, Blood Pressure and Age 
Above or Below 65 Years; FiO2, fraction of inspired oxygen.
Figure 2 Receiver operating characteristic plots for death within 72 hours and ICU admission based on the models 
defined as the sum of the corresponding predictors. Circles denote the sensitivity and specificity achieved by the optimal 
threshold from fitted models. AUC, area under the curve; CUCAF- SR, Clinical Frailty Scale, Urea, Consolidation, Age, FiO2, 
Sex, Respiratory rate; CUCA- SF, Clinical Frailty Scale, Urea, Consolidation, Age, SpO2, FiO2; CURB-65, Confusion, Urea, 
Respiratory Rate, Blood Pressure and Age Above or Below 65 Years; ICU, intensive care unit; NEWS2, National Early Warning 
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Consolidation, Age, SpO2, FiO2 (CUCA- SF)), as shown in 
table 5.
DISCUSSION
We analysed the accuracy with which admission CURB-
65, NEWS2 and qSOFA scores predict ICU admission, 
early in hospital mortality and all- cause mortality within 
30 days of hospital admission in the context of COVID-
19. In general, calibration was poor as all three scores 
underestimated the risk of adverse outcomes. CURB-65 
and qSOFA both performed poorly in comparison to 
their respective standard applications, suggesting their 
Figure 3 Calibration plots of the predicted risk of 30 day mortality (based on published validation studies) for CURB65,15 
NEWS210 and qSOFA16 against observed risk in COVID-19 hospital admissions. CURB-65, Confusion, Urea, Respiratory 
Rate, Blood Pressure and Age Above or Below 65 Years; NEWS2, National Early Warning Score 2; qSOFA, Quick Sequential 
(Sepsis- Related) Organ Failure Assessment.
Table 3 Diagnostic performance of individual scores for 30- day and 72- hour mortality
Score (n) Death (%) Sensitivity Specificity PPV NPV
Death by 30 days     
  CURB-65
  (n=605)*
<2 (273) 46 (16.8) 0.80 0.61 0.57 0.83
≥2 (332) 188 (56.6)
<3 (434) 125 (28.8) 0.47 0.83 0.64 0.71
≥3 (171) 109 (63.7)
  NEWS2
  (n=730)
<5 (215) 46 (21.4) 0.83 0.37 0.43 0.79
  ≥5 (515) 224 (43.5)
  qSOFA
  (n=730)
<2 (596) 196 (32.9) 0.27 0.87 0.55 0.67
≥2 (134) 74 (55.2)
Death within 72 hours
  CURB-65
  (n=605)
<2 (273) 8 (2.9) 0.86 0.48 0.15 0.97
≥2 (332) 49 (14.8)
<3 (434) 22 (5.1) 0.61 0.75 0.20 0.95
≥3 (171) 35 (20.5)
  NEWS2
  (n=730)
  <5 (215) 5 (2.3) 0.92 0.31 0.10 0.98
≥5 (515) 54 (10.5)
  qSOFA
  (n=730)
  <2 (596) 34 (5.7) 0.42 0.84 0.19 0.94
≥2 (134) 25 (18.7)
*Analysis restricted to those with consolidation on chest radiograph.
CURB-65, Confusion, Urea, Respiratory Rate, Blood Pressure and Age Above or Below 65 Years; NEWS2, National Early Warning Score 2; 
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utility is limited in COVID-19. In contrast, NEWS2 and 
CURB-65 were better at predicting early death, defined 
here as death of <72 hours, where a NEWS2 threshold of 
5 (the recommended threshold for urgent intervention) 
showed excellent NPV. We went on to derive two sets of 
parameters which, when combined on admission with 
COVID-19, may provide a more accurate prediction of 
mortality and may provide a useful basis for predictive 
scores to be validated in larger datasets.
CURB-65 was derived and validated to predict low, 
moderate and high risk of death at 30 days in patients 
with CAP and therefore assisted healthcare workers 
in deciding who required admission to the hospital. 
Pre- COVID validation demonstrated a score of <2 was 
consistently associated with low mortality rates of 0.4%–
2.8% at 30 days.6 15 However, here in the COVID-19 
setting, a CURB-65 score of <2 was associated with a 
mortality of 17%. In clinical practice, its utility has been 
expanded to support decision making around antimi-
crobial prescribing and escalation of care. We therefore 
performed an exploration of CURB-65 performance with 
respect to ICU admission and early mortality prediction. 
Our data suggest low CURB-65 scores may not support 
early COVID-19 discharge, but higher scores may still 
have value in predicting particularly poor outcomes; 
CURB-65 scores of ≥3 were associated with death in 60% 
of cases, compared with just 22% in the pre- COVID era.5 
On that basis, high scores could prompt early escalation 
planning and inform discussions with patients and their 
families.
In the pre- COVID era, at the time of presentation 
to hospital with CAP, it was extremely unusual for the 
medical team to know the causal pathogen, and although 
it was well recognised that there was a range of virulence 
among the possible viral and bacterial causes of CAP, 
the data presented here confirm that SARS- CoV-2 is a 
highly virulent outlier. This finding has particular rele-
vance to the evolving pandemic since, as transmission 
reduces, SARS- CoV-2 will become one of numerous 
endemic causes of CAP in many countries. It will there-
fore be important to recognise that this will reduce the 
Table 4 OR of death within 30 days and 72 hours for the 
individual strata of each score
Model Score OR (95% CI) P value
30- day mortality
  CURB-65 0 (reference)
1 4.04 (1.91 to 8.53) <0.001
2 11.56 (5.65 to 23.64) <0.001
3 17.87 (8.46 to 37.73) <0.001
≥4 29.65 (12.59 to 69.82) <0.001
  NEWS2 <5 (reference)
≥5 2.83 (1.95 to 4.09) <0.001
  qSOFA <2 (reference)
≥2 2.52 (1.72 to 3.68) <0.001
72h mortality
  CURB-65 0 (reference)
1 6.64 (0.81 to 54.71) 0.079
2 12.29 (1.59 to 94.71) 0.016
3 18.43 (2.38 to 142.52) 0.005
≥4 71.29 (9.29 to 547.34) <0.001
  NEWS2 <5 (reference)
≥5 4.92 (1.94 to 12.48) 0.001
  qSOFA <2 (reference)
≥2 3.79 (2.18 to 6.61) <0.001
CURB-65, Confusion, Urea, Respiratory Rate, Blood Pressure 
and Age Above or Below 65 Years; qSOFA, Quick Sequential 
(Sepsis- Related) Organ Failure Assessment.
Table 5 Important prognostic variables identified by logistic regression models fitted for 30- day and 72- hour mortality
Outcome Model Estimate (SE) OR (95% CI) P value
30- day mortality CFS score (≥5) 0.94 (0.20) 2.55 (1.74 to 3.74) <0.001*
Urea (>7mmol/L) 0.92 (0.19) 2.50 (1.71 to 3.65) <0.001*
Consolidation 0.71 (0.24) 2.04 (1.26 to 3.29) 0.004*
Age (≥65 years) 0.87 (0.21) 2.39 (1.58 to 3.64) <0.001*
FiO2 (>21) 0.51 (0.18) 1.67 (1.17 to 2.38) 0.005*
Sex (male) 0.43 (0.19) 1.53 (1.06 to 2.22) 0.023
Respiratory rate (≥30 breaths/min) 0.86 (0.22) 2.36 (1.55 to 3.61) <0.001
72- hour mortality CFS score (≥5) 0.96 (0.34) 2.60 (1.34 to 5.06) 0.005
Urea (>7mmol/L) 1.25 (0.43) 3.50 (1.50 to 8.18) 0.004
Consolidation 1.83 (0.74) 6.21 (1.45 to 26.66) 0.014
Age (≥65 years) 0.95 (0.45) 2.59 (1.06 to 6.30) 0.036
SpO2 (≤94) 0.90 (0.31) 2.46 (1.34 to 4.51) 0.004
FiO2 (>21) 1.13 (0.31) 3.08 (1.67 to 5.68) <0.001
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performance of CURB-65 on undifferentiated CAP cases 
and makes a strong case for the implementation of rapid 
diagnostics to determine the aetiology of CAP.
NEWS2 has been widely implemented in English hospi-
tals as a simple score consisting of routine physiological 
measurements. While it is most widely recognised as a 
simple tool to identify inpatients in need of urgent or 
emergent medical attention based on changing physiolog-
ical measurements, it is also often used in the emergency 
department, where it has been validated in a number of 
syndromes, including sepsis and acute dyspnoea.16 17 We 
found that a NEWS2 score of <5 accurately identified a 
group of patients as a low- risk group for early mortality; 
however, it was less successful when 30- day mortality was 
considered. Our findings are based on a single measure 
of NEWS2 on admission, and future longitudinal work 
would be needed to confirm if established NEWS2 trigger 
thresholds remain valid for inpatients with COVID-19.
qSOFA was validated for use among hospital inpa-
tients and emergency department admissions as a simple 
and accurate way to identify people with infections at 
higher risk of poor outcomes.4 11 18 Early data from China 
suggested those who survived COVID-19 had lower 
qSOFA scores, a finding replicated here.19 However, in 
our study, the median qSOFA in those who died within 30 
days was <2, and mortality in this 'low- risk' qSOFA group 
was 32.5%. Taken together, the poor overall discrimina-
tory ability of qSOFA and the poor diagnostic perfor-
mance seen here suggests a qSOFA score on admission is 
not a useful prognostic tool in COVID-19. These findings 
are supported by a recent study which found qSOFA was 
low in people with COVID-19 admitted to critical care 
and could not reliably identify those at risk of death.20
The poor performance of qSOFA is interesting, given 
it was derived from cohorts of patients with sepsis, a 
syndrome defined as a ‘life- threatening organ dysfunc-
tion due to a dysregulated host response to infection’. It 
would be expected that many with COVID-19- associated 
mortality would meet that definition on the basis of respi-
ratory failure. However, the striking difference between 
the physiology of bacterial sepsis and severe COVID-19 
is that cardiovascular instability is rare in COVID-19.18 
In our modelling of individual variables of CURB-65, 
we found that unlike the respiratory components, blood 
pressure was not independently associated with adverse 
outcome. Similarly, confusion, often a sign of haemody-
namic compromise, was less relevant to outcomes in the 
CURB-65 score.
Blood pressure and mental status are integral 
components of the qSOFA score and in other contexts 
contribute to its ability to prognosticate; thus, the poor 
performance of qSOFA is explained by the limited effect 
of COVID-19 on these physiological parameters. These 
findings suggest COVID-19- associated mortality may be 
mediated by different mechanisms than conventional 
bacterial sepsis. An example of this may be the profound 
endothelial injury and abundant microthrombi identi-
fied in a recent postmortem study.21
Given the limited performance of the previously vali-
dated and widely used scores seen here, we explored 
whether performance could be improved by deriving new 
models. Using multiple logistic regression, we derived 
new models, CUCAF- SR and CUCA- SF, in an attempt 
to predict 30- day and 72- hour mortality, respectively. In 
keeping with the findings described earlier, markers of 
cardiovascular compromise were not independently asso-
ciated with poorer outcomes, with markers of respiratory 
function, age and frailty appearing more relevant. This 
finding is supported by the findings of the ISARIC study, 
where respiratory function (respiratory rate and oxygen 
saturations), age and comorbidities, but not cardiovas-
cular parameters, were important constituents of the 4C 
mortality score.22
Some limitations must be addressed. First, we only 
included a 2- week period, and it is possible demo-
graphics and outcomes may change across the course of 
the COVID-19 pandemic.23 Reassuringly, the characteris-
tics and outcomes in the study population seen here are 
in keeping with those reported by the ISARIC study, one 
of the largest studies in this setting to date. For example, 
the median age here was 70 years compared with 72 years 
in the ISARIC study; 61% were male here compared with 
59.9% in ISARIC; 17.1% here were admitted to critical 
care compared with 17% in ISARIC; and we observed 
34% 30- day mortality, which is comparable to the hospital 
case fatality rate of 33.6% reported by ISARIC.24 25
A further limitation here is the inclusion only of those 
people admitted to hospital, thus excluding those well 
enough to be discharged from the emergency depart-
ment. As a consequence, the observed risk presented 
among low- risk categories seen here may, in theory, 
be inflated; for example, it is possible only the sickest 
patients with CURB-65 scores of 0–1 were admitted. 
However, the main derivation dataset for the CURB-65 
score included only patients admitted to the hospital, 
replicating the methods here.5 Similarly, a large validation 
study that included both admissions of those discharged 
directly from the emergency department found that 
30- day mortality in those admitted to hospital with a 
low- risk CURB-65 score remained low at 0.0%–1.6%.15 
This supports the conclusion that the observed high 
mortality among low CURB-65 scores in this study was 
due to SARS- CoV-2 virulence rather than study design. 
Conversely, some patients presented to the emergency 
department in a moribund state and did not survive 
long enough for a viral swab to be taken. Such patients 
were not included in our study, and generalisability to 
that small subset of patients may be limited. Data collec-
tion here did not include assessment of detailed patient 
demographics or comorbidities, but instead focused on 
clinical measurements normally taken at presentation to 
the hospital. Characteristics such as obesity, ethnicity and 
comorbidities are reported to be relevant to COVID-19 
outcomes but are not included here.26 27 It may be that 
a combination of clinical parameters and patient charac-
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validation of such an approach is required.28 We defined 
‘early mortality’ as death occurring within 72 hours of 
admission in order to capture patients who deteriorated 
quickly, but within a time frame that would allow them 
to have a known SARS- CoV-2 status and be identified by 
our investigators. This 72- hour timepoint differs from 
the 24- hour timepoint used in the NEWS2 score’s valida-
tion studies but, given the above constraints, was consid-
ered a pragmatic approach for our analysis. Finally, ICU 
admission is not appropriate for all patients, and our 
analysis of ICU admissions may be prone to unmeasured 
confounding in that regard.
The strengths of this study lie in the prospective collec-
tion of data on consecutive admissions from multiple 
regional hospitals with rigorous assessment of the 
performance of each score. These readily available data 
were compiled from real- world clinical assessment, and 
outcomes followed usual clinical care. We also demon-
strate the hitherto underappreciated potential of highly 
trained and motivated specialty trainees and their ability 
to coordinate and collaborate for research.
CONCLUSION
CURB-65, NEWS2 and qSOFA underestimate 30- day 
mortality among patients admitted to the hospital with 
COVID-19. CURB-65 and NEWS2 were slightly better 
at predicting early mortality. However, our data suggest 
CURB-65 should not be used to prognosticate in the 
setting of COVID-19 pneumonia since low CURB-65 
scores were associated with high mortality rates. We 
provide a set of clinical parameters which appear relevant 
to outcomes in COVID-19 and should be considered in 
future studies aimed at deriving COVID-19- specific prog-
nostic tools.
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